I have been engaged in the research and development of viral vaccines for nearly 20 years. Now my interest is in the development of vaccines for high biosafety grade (BSL-3 and BSL-4) viruses. In 2013, I was admitted to the National Institute for Viral Disease Control and Prevention, Chinese Center for Disease Control and Prevention to pursue a doctoral degree. During this period, I was mainly engaged in the research and development of recombinant protein vaccines, viral vector vaccines, and virus-like particle vaccines of Middle-East respiratory syndrome coronavirus (MERS-CoV) and reported the immune response and protection effect based on the recombinant subunit vaccine of MERS-CoV in a rhesus monkey model for the first time in the world, providing new ideas and technical support for the research and development of coronavirus vaccines. After joining the Pasteur Institute of Chinese Academy of Sciences in Shanghai in 2019, I was mainly engaged in the research and development of nucleic acid (DNA and mRNA) vaccines and recombinant virus-vectored vaccines against Nipah virus, Ebola virus, SARS-CoV-2, Crimean Congo hemorrhagic fever virus, and so on. By now, lots of results have been published in journals such as npj Vaccines, JCI INSIGHT, J. Immunol., J INFECTION, EBIOMEDICINE, VACCINE and Emerging Microbes Infect., VIROL SIN and so on. As the project leader, I undertook the National Natural Science Foundation project and the Shanghai Natural Science Foundation project. As the main researcher, I participated in the pilot plan of Chinese Academy of Sciences, the National Major Special Project on Infectious Diseases, and the National Key Research and Development Project. As the main inventor, I participated in applying for a number of national patents related to vaccines and antiviral drugs.

Selected publications

1.      Lu M^#, Yao Y^{#, *}, Zhang X, Liu H, Zhang X, Li X, Liu Y, Peng Y, Chen T, Sun Y, Gao G, Chen M, Zhao J, Zhang X, Yin C, Guo W Yang P, Hu X, Rao J, Li E, Wong G, Yuan Z^*, Chiu S ^*,Shan C^*,Lan J^* (2023).Vaccines based on consensus sequence of the Fusion protein completely protected the Syrian hamsters against Nipah virus infection of Malaysia and Bangladesh strains. JCI insight, Accepted (^*Co-corresponding author)

2.      Lu M^#, Yao Y^{#, *}, Zhang X, Liu H, Gao G, Peng Y, Chen M, Zhao J, Zhang X, Yin C, Guo W,2, Yang P, Hu X, Rao J, Li E, Chen T, Chiu S, Gary Wong, Yuan Z^*, Lan J^*, Shan C^*(2023). Both chimpanzee adenovirus-based and DNA vaccines induced long-term immunity against Nipah virus infection. NPJ Vaccine, Accepted, (^*Co-corresponding author)

3.      Sun K^#, Ding Z^#, Jia X^#, Cheng H^#, Li Y, Wu Y, Li Z, Huang X, Pu F, Li E, Wang G, Wang W, Ding Y, Gary Wong, Chiu S^*, Lan J^* , Hu A^*(2023). Extracellular Disintegration of Viral Proteins as an Innovative Strategy for Developing Broad-Spectrum Antivirals Against Coronavirus. CCS Chem, 5:1–11. (^*Co-corresponding author)

4.      Lu M^#, Liu K^#, Peng Y^#, Ding Z^#, Li Y, Alexander T, Hu X, Gao G, Guo W, Liu H, Rao J, Zhao J, Chen M, Yuan Z, Wong G^*, Shan C^*, Yao Y^*, Lan J^*(2022). Recombinant chimpanzee adenovirus vector vaccine expressing the spike protein provides effective and lasting protection against SARS-CoV-2 infection in mice. Virol Sin, 37(4):581-590. (^*Co-corresponding author)

5.      Shen L^#, Li S^#, Zhu Y^#, Zhao J^#, Tang X^#, Li H, Xing H, Lu M, Frederick C, Huang C, Wong G^*, Wang C^*, Lan J^*(2020). Clinical and Laboratory-Derived Parameters of 119 Hospitalized Patients with Coronavirus Disease 2019 in Xiangyang, Hubei Province, China. J Infect, pii: S0163-453(20)30166-3. (^*Co-corresponding author)

6.      Shen L^#, Wang C^#, Zhao J^#, Tang X^#, Shen Y^#, Lu M, Ding Z, Huang C, Zhang J, Li S, Lan J^*, Wong G^*, Zhu Y^*(2020). Delayed specific IgM antibody responses observed among COVID-19 patients with severe progression. Emerg Microbes Infect, 9(1):1096-1101. (^*Co-corresponding author)

7.      Kuo S, Lan J^*(2020). Progress on Research Tools of Coronaviruses. Chinese Journal of Virology, 2020 (02): 306–313. (^*Corresponding Author).

8.      Yang R^#, Lan J^#, Huang B, A R, Lu M, Wang W, Wang W, Li W, Deng Y^*, Wong G^*, Tan W^*(2020). Lack of antibody-mediated cross-protection between SARS-CoV-2 and SARS-CoV infections. EBioMedicine, 58:102890. (#Co-First Author).

9.      Lan J, Deng Y, Song J, Huang B, Wang W, Tan W^*(2018). Significant Spike-Specific IgG and Neutralizing Antibodies in Mice Induced by a Novel Chimeric Virus-Like Particle Vaccine Candidate for Middle East Respiratory Syndrome Coronavirus. Virol Sin, 33(5):453-455. (First Author).

10.   Deng Y^#, Lan J^#, Bao L^#, Huang B, Ye F, Chen Y, Yao Y, Wang W, Qin C, Tan W^*(2018). Enhanced protection in mice induced by immunization with inactivated whole viruses compare to spike protein of middle east respiratory syndrome coronavirus. Emerg Microbes Infect, 7(1):60. (#Co-First Author).

11.   Lan J^#, Yao Y^#, Deng Y^#, Hu Y, Bao L, Huang B, Yan J, Gao GF, Qin C, Tan W^*(2017). The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection.Vaccine, 35(1):10-18. (#Co-First Author).

12.   Liu WJ^#, Lan J^#, Liu K^#, Deng Y^#, Yao Y^#, Wu S, Chen H, Bao L, Zhang H, Zhao M, Wang Q, Han L, Chai Y, Qi J, Zhao J, Meng S, Qin C, Gao GF^*, Tan W^*(2017). Protective T Cell Responses Featured by Concordant Recognition of Middle East Respiratory Syndrome Coronavirus-Derived CD8⁺ T Cell Epitopes and Host MHCJ Immuno, 198(2):873-882. (#Co-First Author).

13.   Lan J^#, Yao Y^#, Deng Y^#, Chen H, Lu G, Wang W, Bao L, Deng W, Wei Q, Gao GF, Qin C^*, Tan W^*(2015). Recombinant Receptor Binding Domain Protein induces Partial Protective Immunity in Rhesus Macaques against Middle East Respiratory Syndrome Coronavirus Challenge. EBioMedicine,2(10):1438-1446. (#Co-First Author).